Welcome to “Debunking Value, Access & Pricing Myths”—a podcast series from IQVIA’s Value and Payer Evidence team where we explore the transformations underway in healthcare pricing and market access - challenging outdated norms and shedding light on the new realities shaping our work.
In the second episode, your host Rebecca Coady, Principal at IQVIA, is joined by her colleague Katrin Lamp. Together, they take on a myth “Pricing in Germany is always transparent.”
Katrin, who is a principal at IQVIA and an expert in the German market, shares her perspectives on the major changes to drug pricing in the largest EU pharmaceutical market, Germany, and what this means for pricing strategy development and price management – they cover what you need to know about the changing pricing rules, including the opportunity for confidential pricing.